We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Takeda Pharmaceutical Company has exercised its option to acquire Maverick Therapeutics for a pre-negotiated upfront payment and potential development and regulatory milestones totalling up to $525m.
The funding will be utilized for the company's development of its medical artificial intelligence-based solutions for identifying chronic disease in elderly populations.